Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Adult cardiac surgery during COVID-19 lockdown: Impact on activity and outcomes in a high-volume centre

Conséquences de la pandémie COVID-19 sur l’activité de chirurgie cardiaque adulte et résultats cliniques : expérience rennaise

Joseph Nader a,1,2, Amedeo Anselmi a,1,*, Jacques Tomasi a, Amandine Martin a, Marie Aymami a, Simon Rouze a, Hervé Corbineau a, Thierry Langanay a, Erwan Flecher a, Nicolas Nesseler b, Jean-Philippe Verhoye a

a Division of thoracic and cardiovascular surgery, Rennes university hospital, 35000 Rennes, France
b Division of cardiac anaesthesia, Rennes university hospital, 35000 Rennes, France

Received 7 November 2020; received in revised form 9 December 2020; accepted 22 December 2020
Available online 22 January 2021

Summary
Background. — The coronavirus disease 2019 (COVID-19) outbreak had a direct impact on adult cardiac surgery activity, which systematically necessitates a postoperative stay in intensive care.

Aim. — To study the effect of the COVID-19 lockdown on cardiac surgery activity and outcomes, by making a comparison with the corresponding period in 2019.

KEYWORDS
COVID-19; Adult cardiac surgery; Public health

Abbreviations: COVID-19, coronavirus disease 2019; EuroSCORE, European System for Cardiac Operative Risk Evaluation; ICU, intensive care unit; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SFCTCV, French Society of Thoracic and Cardiovascular Surgery (Société française de chirurgie thoracique et cardiovasculaire).
Methods. — This prospective observational cohort study compared adult cardiac surgery activity in our high-volume referral university hospital from 9 March to 10 May 2020 versus 9 March to 10 May 2019. Data were collected in our local certified database and a national database sponsored by the French society of thoracic and cardiovascular surgery. The primary study endpoints were operative mortality and postoperative complications.

Results. — With 105 interventions in 2020, our activity dropped by 57% compared with the same period in 2019. Patients were at higher risk, with a significantly higher EuroSCORE II score (3.8 ± 4.5% vs. 2.0 ± 1.8%; P < 0.001) and higher rates of active endocarditis (7.6% vs. 2.9%; P = 0.047) and recent myocardial infarction (9.5% vs. 0%; P < 0.001). The weight and priority of the interventions were significantly different in 2020 (P = 0.019 and P < 0.001, respectively). The rate of acute aortic syndromes was also significantly higher in 2020 (P < 0.001). Operative mortality was higher during the lockdown period (5.7% vs. 1.7%; P = 0.038). The postoperative course was more complicated in 2020, with more postoperative bleeding (P = 0.003), mechanical circulatory support (P = 0.032) and prolonged mechanical ventilation (P = 0.005). Only two patients (1.8%) developed a positive status for severe acute respiratory syndrome coronavirus 2 after discharge.

Conclusions. — Adult cardiac surgery was heavily affected by the COVID-19 lockdown. A further modulation plan is necessary to improve outcomes and reduce postponed operations to decrease operative mortality and morbidity.

© 2021 Elsevier Masson SAS. All rights reserved.

Background

With more than 80 million patients tested positive to date and more than 2,000,000 global deaths [1], coronavirus disease 2019 (COVID-19), caused by infection with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared a global pandemic by the World Health Organisation. Since the emergence of this virus in December 2019 in Wuhan (China) [2], it has spread quickly worldwide. At the time of writing, France was the eleventh country in the world by absolute number of confirmed cases (n = 266,040) [1]. Drastic measures were taken by different countries to prevent local health infrastructures being overwhelmed and the ensuing increased mortality in high-risk
patients. In France, national lockdown was declared by the
government for a total of 8 weeks, starting on 17 March
2020. All hospitals and clinics were asked to modify their
intensive care unit (ICU) capacities, and to be ready for any
surge in critically ill patients requiring advanced respiratory
support.

Cardiac surgery systematically requires postoperative
intensive care. As these specialised units were reserved for
patients with COVID-19 necessitating respiratory support,
elective open-heart surgeries were substantially delayed in
almost all French centres; this raised concerns about patient
safety while on the waiting list. A careful risk/benefit eval-
uation is required for candidates for cardiac surgery, as
hospitals have been identified as the main sites of SARS-CoV-
2 viral transmission, and cardiac comorbidity is associated
with a more severe course of the disease.

The scientific committee and directory board of the
French society of thoracic and cardiovascular surgery
(Société française de chirurgie thoracique et cardiovascu-
laire [SFCTCV]) announced, starting on 17 March 2020, a
guidance statement for triage of surgical candidates
during this COVID-19 pandemic. This system is based on a
"three-colour" stratification of patients on the waiting list
(Table 1), corresponding to recommended delays to surgi-
cal treatment in the pandemic context. Other experts in
cardiology and cardiothoracic surgery published similar rec-
ommendations in their respective countries, with patient
admission and management purposes [3—6].

Our aim was to evaluate the impact of the COVID-19
pandemic and the associated restrictive measures on the
features and outcomes of cardiac surgical activity in a
tertiary referral centre in France. Features and outcomes
observed during the lockdown period (9 March to 10 May
2020) were compared with those in the corresponding time
period in 2019. We discuss the relevant measures to prevent
SARS-CoV-2 contamination, and their effect on the popula-
tion of cardiac surgery recipients and on clinical results.

Methods

Epidemic situation and context

Our centre is located in the Brittany region of France (with
a population of around 3,329,000 inhabitants) and was identi-
fied as the regional reference for management of SARS-CoV-2
positive cases. In this western part of the country, the inci-
dence of COVID-19 was lower than in eastern regions. The
first French cluster was identified in the eastern city of
Mulhouse, where a communitarian meeting took place in
February 2020 with more than 2500 people and was identi-
fied as a major spreader event. In Brittany, the first cluster
was identified in a southern county of the region. The peak
of COVID-19 admissions was predicted to occur in France and
in Brittany between 30 March and 6 April 2020 [7]. With the
ensuing national lockdown, unauthorised travel throughout
the entire country was prohibited, and closure of almost all
commodities and collective services was imposed. A national
emergency plan was declared, and all university hospitals and
tertiary healthcare facilities were asked to prepare for
any surge of patients in urgent need of respiratory support
to ICUs.

Before the start of the crisis, our cardiothoracic surgery
department entailed 17 dedicated ICU beds and eight post-
interventional care beds. From 12 March 2020, these units
were mandated to function as polyvalent intensive care
facilities; they received patients requiring urgent non-
cardiac surgery, trauma patients and cases requiring medical
intensive care, with the other ICUs within the hospital being
dedicated to managing patients infected with SARS-CoV-2.
Therefore, the capacity to receive patients after cardiac
surgery was significantly diminished compared with the pre-
lockdown period.

We modified our operating schedule in accordance with
national and scientific guidelines (Table 1). Patients who
were scheduled for an intervention during the initial lock-
down period had their procedure postponed for a minimum
of 4 weeks. Each postponed patient was accorded a priority
degree according to the SFCTCV recommendations. Surgeons
conducted telephone interviews with their patients, and
assessed the risks associated with postponement of car-
diac surgery. Telephone interviews were repeated 3 weeks
later, to make a new evaluation of the clinical status of
the patients on the waiting list, and to potentially reclassify
them according to the SFCTCV guidelines.

Study design

We conducted a prospective single-centre study of car-
diac surgery activity in our Cardiothoracic and vascular
surgery department, which is among the top five centres in
France, performing more than 1300 open-heart surgeries
per year. All data pertaining to cardiac surgery recipients in
our department (including, pre-, intra- and postoperative
data until hospital discharge) are prospectively collected
within the SFCTCV national database "EPICARD". This
database has been modified since the COVID-19 crisis in
France to include any known COVID-19 test results or related
clinical symptoms before admission, as well as whether post-
ponement of the intervention, was required with respect
to the initial schedule because of the pandemic situa-
tion. Additionally, the same data are entered into a local
prospective database, registered in the National Commiss-
tee for Informatics and Freedom (Commission nationale de
l'informatique et des libertés [CNIL]) archive under the
number 1207754. Both databases are approved by local and
national ethic boards. Operative mortality and morbidity
were defined as occurring within the 30th postoperative day,
or later if during the same hospitalisation. The European
system for cardiac operative risk evaluation (EuroSCORE II
score was obtained for all patients according to the calcul-
ator available online at www.euroscore.org.

Patients were followed up after discharge, for up to
2 months. A telephone interview was carried out in June
2020, and information about the post-discharge course was
recorded; this included out-of-hospital mortality, morbidity
and clinically/biologically confirmed infection with SARS-
CoV-2 virus, occurring up to 2 months after cardiac surgery.

The primary study endpoints were in-hospital mortal-
ity and postoperative complications among cardiac surgery
recipients during the period from 9 March to 10 May 2020.
Secondary endpoints were 30-day survival and COVID-19 sta-
tus during or after the hospital stay. All outcome measures

366
were compared with those observed one year earlier, during the period from 9 March to 10 May 2019.

**Statistical analysis**

Continuous data are presented as means ± standard deviations or as medians if not normally distributed. Categorical data are presented as counts and percentages. Intergroup comparison was performed using the two-tailed Student’s t-test and the Mann-Whitney U test. The alpha level was 0.05. Analyses were conducted using the statistical package for social sciences (SPSS) software for Windows (IBM, Armonk, NY, USA).

**Results**

During the period from 9 March to 10 May 2020, 105 patients underwent cardiac surgery in our department, representing a 57% drop compared with the same period in 2019 (105 vs. 242 patients). Seventy-nine patients were male (75%) and the mean age was 66.2 ± 10.8 years. The baseline characteristics of patients in the 2020 cohort are presented in Table 2 and are compared with the 2019 patient group. Mean body mass index was significantly lower compared with the 2019 cohort, \( P < 0.001 \), whereas preoperative creatinine clearance was significantly greater in the 2020 cohort (86.6 ± 39.1 vs. 64.7 ± 27.9 mL/min; \( P < 0.001 \)). Also, the mean preoperative EuroSCORE II score was significantly higher in 2020 (3.8 ± 4.5% vs. 2.0 ± 1.8%; \( P < 0.001 \)). Concordantly, activity in 2020 was characterised by statistically higher rates of active endocarditis (7.6% vs. 2.9%; \( P = 0.047 \)) recent acute myocardial infarction (9.5% vs. 0%; \( P < 0.001 \)) and patients admitted with a critical preoperative status (preoperative administration of inotropes and/or circulatory mechanical support) \( P < 0.001 \). The distribution of weight of interventions (as defined by EuroSCORE II) (Fig. 1) and their priorities were significantly different between cohorts \( P = 0.019 \) and \( P < 0.001 \), respectively. The 2020 activity entailed a significantly higher rate of urgent/emergency cases (Fig. 2). Both the rate and absolute number of non-elective cases were higher in 2020 (Table 2). The rate of acute aortic syndromes (including aortic dissection, intramural hematoma and penetrating aortic ulcer) receiving non-elective surgical treatment was also significantly greater in 2020 \( P < 0.001 \) (Table 2).

Operative mortality was significantly higher during the lockdown period (5.7% vs. 1.7%; \( P = 0.038 \)). One of the patients who died was operated on for a post-infarction ventricular septal defect, after documented SARS-CoV-2 infection 2 weeks earlier; he died later of myocardial fail-

---

**Table 1** French society for thoracic and cardiovascular surgery (SFCTCV) guidelines for the management of cardiac surgery candidates.

| Category | Clinical condition | Delay |
|----------|--------------------|-------|
| Emergency | Any patient admitted for: | Immediate |
|          | — acute aortic dissection | |
|          | — acute refractory cardiogenic shock necessitating salvage or emergent intervention | |
| Red      | Syncopal aortic stenosis | < 15 days |
|          | Ascending aortic aneurysm > 60 mm | |
|          | Left-sided highly embolic cardiac tumour | |
|          | Acute coronary syndrome with surgical indication | |
|          | Active infective endocarditis | |
| Orange   | Left-sided valve disease with at least one among: | 2–4 weeks |
|          | — LVEF < 50% | |
|          | — SPAP > 60 mmHg | |
|          | — furosemide treatment > 120 mg/day | |
|          | Left main disease or any chronic stable coronary disease necessitating surgical treatment | |
| Green    | Any surgical cardiac disease for which a greater delay might worsen the final outcome | > 4 weeks |

Each category was assigned a maximum period of time for intervention. LVEF: left ventricular ejection fraction; SPAP: systolic pulmonary artery pressure; SFCTCV: Société française de chirurgie thoracique et cardiovasculaire.
Table 2  Baseline patient characteristics.

|                      | 2019 (n = 242) | 2020 (n = 105) | P  |
|----------------------|----------------|----------------|----|
| Preoperative         |                |                |    |
| Age (years)          | 67 ± 13.2      | 66.2 ± 10.8    | 0.57|
| Male sex             | 162 (66.9)     | 79 (75.2)      | 0.12|
| Body mass index (kg/m²) | 1.87 ± 0.23  | 1.92 ± 0.23    | 0.08|
| Preoperative creatinine (µmol/L) | 88.5 ± 61.9  | 95.4 ± 76.1    | 0.38|
| Creatinine clearance (mL/min) | 64.7 ± 27.9  | 86.6 ± 39.1    | <0.001|
| LVEF (%)             | 60.3 ± 10.8    | 58.2 ± 13.6    | 0.13|
| SPAP (mmHg)          | 31.3 ± 7.9     | 30.1 ± 10.1    | 0.25|
| Active infectious endocarditis | 7 (2.9)  | 8 (7.6)       | 0.047|
| Acute aortic syndrome | 1 (0.4)      | 9 (8.6)       | <0.001|
| Recent AMI           | 0 (0)          | 10 (9.5)       | <0.001|
| Critical preoperative state | 0 (0)      | 11 (10.5)     | <0.001|
| EuroSCORE II score (%) | 2.0 ± 1.8    | 3.8 ± 4.5     | <0.001|
| Priority             |                |                | <0.001|
| Elective             | 221 (91.3)     | 48 (45.7)      |    |
| Urgent               | 20 (8.3)       | 41 (39)        |    |
| Emergency            | 0 (0)          | 12 (11.4)      |    |
| Salvage              | 1 (0.4)        | 4 (3.8)        |    |

Data are expressed as mean ± standard deviation or number (%). AMI: acute myocardial infarction; EuroSCORE: European System for Cardiac Operative Risk Evaluation; LVEF: left ventricular ejection fraction; SPAP: systolic pulmonary artery pressure.

Table 3  Intra- and postoperative outcomes.

|                      | 2019          | 2020          | P  |
|----------------------|---------------|---------------|----|
| CPB time (minutes)   | 86.6 ± 47.6   | 115.2 ± 103.2 | 0.001|
| CC time (minutes)    | 73.2 ± 30.4   | 82.0 ± 36.3   | 0.029|
| Any complication     | 24 (9.9)      | 47 (44.8)     | <0.001|
| Postoperative bleeding | 7 (2.9)  | 11 (10.5)     | 0.003|
| IABP                 | 2 (1.9)       | 0.032         |    |
| ECLS                 | 3 (1.2)       | 7 (6.7)       | 0.006|
| Prolonged intubation | 4 (1.7)       | 8 (7.6)       | 0.005|
| Reintubation         | 3 (2.9)       | 0.008         |    |
| Pulmonary infection  | 14 (5.8)      | 5 (4.8)       | 0.70|
| Mediastinitis        | 1 (0.4)       | 2 (1.9)       | 0.17|
| Stroke               | 4 (1.7)       | 1 (1)         | 0.62|
| AKI with dialysis    | 3 (1.2)       | 4 (3.8)       | 0.12|
| Operative mortality  | 4 (1.7)       | 6 (5.7)       | 0.038|

Data are expressed as mean ± standard deviation or number (%). AKI: acute kidney injury; CC: cross-clamp; CPB: cardiopulmonary bypass; ECLS: extracorporeal life support; IABP: intra-aortic balloon pump.

Complications occurred more frequently in 2020 (in 44.8% vs. 9.9% of patients; P < 0.001) (Table 3), including postoperative bleeding (P = 0.003), mechanical support, such as an intra-aortic balloon pump (P = 0.032) or extracorporeal life support (P=0.006), prolonged mechanical ventilation (P=0.005) and reintubation (P=0.008). We did not observe any significant difference in postoperative pulmonary infections (P=0.70) or mediastinitis (P=0.17). One patient was transplanted, and two patients were implanted with a long-term mechanical circulatory support device. Five patients underwent transcatheter aortic valve implantation. Postoperative stay was shorter in 2020 (10.1 vs. 11 days).

Two patients (1.8%), both of whom were operated on before 16 March 2020, developed SARS-CoV-2 infection following their cardiac operation; they were discharged home, and were alive at the 2-month follow-up.

Finally, five patients on the waiting list died after their operation was postponed. Three of these patients were initially scheduled for coronary artery bypass grafting for three-vessel disease; the other two were waiting for carotid transcatheter aortic valve replacement. The causes of death
Nonetheless, the pandemic period experienced an imbalance in the priority of cardiac surgery. Among patients with life-threatening cardiac diseases, surgical indication was foreseen by the middle of April 2020 [5]. We present the first detailed analysis of adult cardiac surgery activity during the COVID-19 lockdown period in a tertiary referral centre, including a comparison with activity during the same period in 2019. Given the life-threatening nature of cardiac diseases with surgical indication, dedicated planning of healthcare system resources will be required in the context of a COVID-19 second wave or other outbreaks. These original data underline the priority that should be attributed to the cardiac surgery department resuming elective activity, and substantiate previous recommendations [8]. The current observations were obtained from a country in Western Europe that was affected by the pandemic before other regions of the world, where earlier epidemiological phases are currently being experienced.

At the time of writing, France was the eleventh country in the world by number of confirmed COVID-19 cases. Nonetheless, significant imbalances existed between regions with respect to the number of confirmed cases; the western part of the country, where our hospital is located, was characterised by a remarkably lower incidence. The national emergency plan entailed transfer of critical patients from other regions of the country to our hospital. Hence, as a result of the shortage of ICU beds and ventilators, our cardiac surgical activity dropped by 57%. Patients were mainly admitted for urgent or emergency intervention (patients who had not had a previous intervention and were not classified according to the SFCTCV recommendations) and had an overall more severe risk profile at admission. Non-elective indications occurred not only with a significantly higher rate than in 2019, but their absolute number was also markedly greater than one year previously (Central illustration). Concordantly, the operative mortality and morbidity rates were significantly higher versus those observed in 2019. It can therefore be expected that the average hospital resource consumption per patient will be greater than for the corresponding 2019 period. Several factors can be proposed to explain these observations. The postponement of scheduled surgery for severe coronary or valvular disease exposes patients to a time-incremental risk of decompensation and admission in more critical conditions. Admissions to cardiology departments have decreased during the crisis [9,10], thus limiting the capacity for diagnosis and exploration of heart disease. Finally, SARS-CoV-2 has a tropism for the cardiovascular system, and its role in accelerating or destabilising cardiovascular diseases is not fully understood [11]. Therefore, the organisation of healthcare services should entail identification of reference cardiac surgery centres with sufficient resources to manage a surge in non-elective and more complex cases during similar outbreak settings, including a second COVID-19 wave, with or without institution of a second lockdown. Such organisation should be orchestrated at a national level and modulated on a regional basis, depending on differential degrees of viral circulation in individual regions.

In our series, two cardiac surgery patients (1.8%) developed a SARS-CoV-2 positive status after their cardiac operation. After the institution of separate hospital pathways for patients with a SARS-CoV-2 positive status during the earliest phases of the lockdown period, no additional cases of SARS-CoV-2 infection occurred among patients operated on after 16 March 2020. A “one room—one patient” strategy and the rigorous selection of candidates by surgical priority (Table 1) were part of the institutional protocols to minimise the risk of nosocomial SARS-CoV-2 spread in this population.

Our study has some limitations; the short time period was perhaps a major confounding factor.

**Conclusions**

The COVID-19 pandemic heavily affected cardiac surgery activity, with an increased incidence of urgent/emergency cases, resulting in a higher rate of postoperative adverse events. Facing the risk of a second COVID-19 wave, a resource modulation plan should be developed to decrease the rate of postponed operations and to allow selected centres to manage relevant non-elective and complex surgical candidates.
Acknowledgments

The authors are thankful to Dr Calixte De La Bourdonnaye, Mrs Melanie Allainmat and Mrs Sylvie Marie for their invaluable help in data gathering and management.

Disclosure of interest

The authors declare that they have no competing interest.

References

[1] Johns Hopkins University & Medicine. Coronavirus Resource Centre. Available at: https://coronavirus.jhu.edu.
[2] Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–33.
[3] Belluschi I, De Bonis M, Alfieri O, et al. First reorganisation in Europe of a regional cardiac surgery system to deal with the coronavirus-2019 pandemic. Eur J Cardiothorac Surg 2020.
[4] Bonalumi G, di Mauro M, Garatti A, et al. The COVID-19 outbreak and its impact on hospitals in Italy: the model of cardiac surgery. Eur J Cardiothorac Surg 2020;57:1025–8.
[5] Chieffo A, Stefanini GG, Price S, et al. EAPCI position statement on invasive management of acute coronary syndromes during the COVID-19 pandemic. Eur Heart J 2020;41:1839–51.
[6] Hassan A, Arora RC, Adams C, et al. Cardiac surgery in Canada during the COVID-19 pandemic: a guidance statement from the Canadian Society of Cardiac Surgeons. Can J Cardiol 2020;36:952–5.
[7] Massonnaud C, Roux J, Crépey P. Forecasting short term hospital needs in France. Available at: https://sfar.org/covid-19-forecasting-short-term-hospital-needs-in-france/.
[8] Chikwe J, Gaudino M, Hameed I, et al. Committee recommendations for resuming cardiac surgery activity in the SARS-CoV-2 era: guidance from an international cardiac surgery consortium. Ann Thorac Surg 2020;110:725–32.
[9] De Rosa S, Spaccarotella C, Basso C, et al. Reduction of hospitalisations for myocardial infarction in Italy in the COVID-19 era. Eur Heart J 2020;41:2083–8.
[10] Metzler B, Siostrzonek P, Binder RK, Bauer A, Reinstadler SJ. Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage. Eur Heart J 2020;41:1852–3.
[11] Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J 2020;41:1798–800.